Elligo secures partners for federal RWE project to harmonize data models

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/elenabs)
(Image: Getty/elenabs)
Elligo Health Research is partnering with Flatiron Health and the University of Chicago to develop and pilot a common data architecture as part of an FDA-led project.

The federal project led by the US Food and Drug Administration (FDA) aims to test the agency’s harmonization model, part of the common data architecture.

The FDA awarded Elligo​ an award to evaluate the use of harmonized data models to gather real-world evidence (RWE)​ in October of last year, at which time the company was vetting specific data sources.

Now, Flatiron Health and the University of Chicago have agreed to provide de-identified or aggregated datasets for the safety assessment of new oncology therapies through various electronic health record systems.

Both organizations have electronic health record (EHR) systems with real-world data that will be harmonized through the project, said Rebecca Kush, PhD, scientific innovation officer at Elligo Health Research.

The company is still working to add additional partners to join the project, she told us.

“The project’s goal is to harmonize various data models so that important data can be more easily shared and interpreted, resulting in data architecture that will allow easier data exchange,”​ Kush explained.

“If the project is successful, the FDA will be able to receive data in their required format regardless of the current common data model being used by the partner,” ​she said.

Project partners are currently being asked for data in several formats, including PCORnet​, OHDSI​, i2b2​, and Sentinel. The reference model being used for the harmonization is the BRIDG model, ​which Kush said “has a larger scope than the other models and is an HL7​, CDISC​, and ISO​ standard.”

However, “Right now, it is poorly understood and unappreciated,” ​she noted.

The FDA is working directly with two other partners on the project, which involves a number of federal agencies and is slated to run for 18 months.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more